FLERIE.ST Flerie
- Market cap
- SEK 1.14B
- P/E
- -
- P/B
- 0.37x
- ROE
- -18.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is FLERIE.ST undervalued?
Graham numberThe Graham number of Flerie cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Flerie fundamental analysis
No fundamental analysis for Flerie yet.
Flerie stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Flerie
Flerie AB (publ) is a venture capital firm specializing in early-stage investments. The firm seeks to invest in life science, biotech and pharma companies engaged in drug development and associated tools or applications tackling major medical challenges of our time. The firm seeks to invest in Europe, Nordic, United States and Israel. Flerie AB (publ) was founded in 2011 and is based in Stockholm, Sweden with additional office in London, United Kingdom.
Full company profileFlerie financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Flerie annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 176K | 113K | 128K | 88.0K | 35.0K | - | 0.00 | 97.5M | 100K | 8.80M | -10.1M |
| Gross Profit | -39.8M | -73.3M | -82.6M | -87.7M | -57.7M | -1.25M | -1.07M | 93.3M | -41.6M | -12.7M | -30.5M |
| Operating Income | -39.8M | -73.3M | -82.6M | -87.7M | -57.7M | -116M | -151M | -107M | -111M | -782M | -548M |
| EBITDA | -39.5M | -72.7M | -81.1M | -86.8M | -56.1M | -102M | -99.1M | -93.8M | -226M | -744M | -457M |
| Net Income | -41.3M | -72.8M | -82.1M | -87.8M | -57.4M | -103M | -100M | -95.3M | -228M | -757M | -579M |
| EPS | -2.48 | -4.36 | -4.84 | -4.46 | -2.43 | -2.13 | -1.88 | -1.79 | -3.24 | -9.71 | -6.68 |
| Balance Sheet | |||||||||||
| Total Assets | 194M | 127M | 86.4M | 129M | 61.2M | 445M | 351M | 299M | 4.22B | 3.40B | 3.19B |
| Total Liabilities | 17.0M | 22.1M | 21.9M | 22.6M | 11.9M | 11.2M | 17.4M | 60.5M | 25.3M | 20.3M | 75.5M |
| Shareholders' Equity | 177M | 105M | 64.5M | 107M | 49.3M | 434M | 334M | 239M | 4.20B | 3.38B | 3.11B |
| Cash & Short-term Investments | 193M | 125M | 83.0M | 127M | 53.8M | 428M | 345M | 294M | 865M | 540M | 265M |
| Total Debt | - | - | 1.43M | 484K | 2.34M | 1.28M | 3.25M | 2.30M | 800K | 2.10M | 1.60M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -31.9M | -68.2M | -78.6M | -85.1M | -70.7M | -124M | -129M | -38.0M | -17.0M | -28.1M | -36.9M |
| Capital Expenditure | 53.0K | 0.00 | 0.00 | 0.00 | 909K | 0.00 | 0.00 | 0.00 | 0.00 | 28.1M | 0.00 |
| Free Cash Flow | -31.9M | -68.2M | -78.6M | -85.1M | -71.6M | -124M | -129M | -38.0M | -17.0M | -28.1M | -36.9M |
| Ratios | |||||||||||
| ROE | -23.3% | -69.5% | -127.4% | -82.4% | -116.4% | -23.7% | -30.0% | -39.9% | -5.4% | -22.4% | -18.6% |
| ROA | -21.2% | -57.3% | -95.1% | -68.0% | -93.8% | -23.1% | -28.6% | -31.8% | -5.4% | -22.3% | -18.2% |
| Net Profit Margin | -23,451.7% | -64,388.5% | -64,178.1% | -99,742.0% | -164,051.4% | - | - | -97.7% | -228,000.0% | -8,601.1% | - |
| Debt to Equity | - | - | 0.02x | 0.00x | 0.05x | 0.00x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Flerie dividends
Flerie has not paid dividends in the last 9 fiscal years.
Last stock split: 8:7 on May 15, 2026.
Who owns Flerie
- Insiders 74.93%
- Institutions 15.35%
- Public & others 9.72%
- Shares outstanding 89.4M
- Free float 22.4M
Flerie company profile
- Company name
- Flerie
- Ticker
- FLERIE.ST
- ISIN
- SE0022447348
- Exchange
- Stockholm Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Fiscal year end
- December
- Address
- Skeppsbron 16, Stockholm, Sweden, 111 30
- Phone
- 46 (0)76 131 01 27
- Website
- flerie.com
About Flerie
Flerie AB (publ) is a venture capital firm specializing in early-stage investments. The firm seeks to invest in life science, biotech and pharma companies engaged in drug development and associated tools or applications tackling major medical challenges of our time. The firm seeks to invest in Europe, Nordic, United States and Israel. Flerie AB (publ) was founded in 2011 and is based in Stockholm, Sweden with additional office in London, United Kingdom.
Flerie management
6- Mr. Thomas Eldered M.Sc.Executive Chairman of the Board · born 1960
- Dr. Ted Fjallman Ph.D.Chief Executive Officer · born 1978
- Ms. Cecilia Stureborg von ScheeleCFO & Deputy CEO · born 1972
- Mr. José Manuel OchoaVenture Partner · born 1961
- Mr. Arvid Söderhäll Ph.D.Venture Partner
- Mr. Fredrik Lehmann M.B.A., Ph.D.Senior Advisor · born 1976